) During an allograft rejection response, host CD4+ T-cells can recognize donor alloantigens either directly by recognition of mismatched donor MHC class II alloantigens expressed on donor APC, or indirectly by recognition of processed donor alloantigens (MHC or non-MHC) in association with self class II expressed on recipient APC. The role of the direct pathway in allograft reaction is well characterized but little is known about the indirect pathway, despite the fact that it is the physiologic route of antigen recognition and is therefore likely to be a potent element of the antidonor response. This proposal seeks to determine the importance of the indirect pathway in allograft rejection, toward the ultimate goal of developing therapeutic strategies for clinical transplantation that render it ineffective. The fundamental strategy for the proposed experiments is to examine the nature of the immune response when donor grafts that lack class II are placed on normal recipients (i.e., the direct pathway is absent but indirect is intact) compared to that when donor grafts that express class II are placed on recipients that do not (i.e., direct pathway is intact but indirect is absent). These experiments are now feasible due to the recent development of genetically engineered mice that either fail to express class II antigens or express class II only on selected cell types. The proposed studies, using both in vivo and in vitro techniques, will be directed at three specific aims: 1) to determine how T cell responses generated by the indirect pathway compare and contribute to direct responses in cell-mediated rejection of skin grafts; 2) to determine why and how the indirect response is essential for the differentiation of alloantibody forming B-cells; and 3) to explore the failure of direct and indirect stimulation to cause vigorous rejection of primarily vascularized organ transplants.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI038397-04
Application #
2672558
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
1995-07-01
Project End
2000-06-30
Budget Start
1998-07-01
Budget End
1999-06-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02199
Yamada, Akira; Laufer, Terri M; Gerth, Andrea J et al. (2003) Further analysis of the T-cell subsets and pathways of murine cardiac allograft rejection. Am J Transplant 3:23-7
Yamada, A; Kishimoto, K; Dong, V M et al. (2001) CD28-independent costimulation of T cells in alloimmune responses. J Immunol 167:140-6
Yamada, A; Chandraker, A; Laufer, T M et al. (2001) Recipient MHC class II expression is required to achieve long-term survival of murine cardiac allografts after costimulatory blockade. J Immunol 167:5522-6
Sabatine, M S; Laufer, T; Glimcher, L H et al. (1998) Delayed rejection of soluble tumor necrosis factor receptor-secreting tumor allografts. Transplantation 65:113-20
Auchincloss Jr, H; Sultan, H (1996) Antigen processing and presentation in transplantation. Curr Opin Immunol 8:681-7